TaiMed Biologics Inc. (TPEX:4147)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
56.50
-1.50 (-2.59%)
Jul 29, 2026, 1:30 PM CST

TaiMed Biologics Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
601.19611.35610.16491.78563.01413.44
Revenue Growth
-1.03%0.19%24.07%-12.65%36.18%-42.77%
Gross Profit
271.98259.45211.23225.23215.7183.96
Operating Income
-159.05-194.65-252.27-166.23-191.86-486.37
Net Income
-125.62-167.78-201.83-194.81-269.29-470.93
Earnings Per Share
-0.46-0.61-0.75-0.77-1.07-1.87
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1,6351,7681,652646.5642.79958.3
Total Debt
485.65493.12522.63750.86766.14567.32
Net Cash (Debt)
1,1491,2751,130-104.35-123.35390.98
Net Cash Growth
-0.99%12.86%----38.12%
Net Cash Per Share
4.214.674.21-0.41-0.491.55

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
100.37191.14-379.55-25.6-605.21-211.28
Capital Expenditures
-22.7-22.67-8.06-6.15-3.56-9.69
Free Cash Flow
77.67168.48-387.61-31.75-608.77-220.96
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
45.24%42.44%34.62%45.80%38.31%20.31%
Operating Margin
-26.46%-31.84%-41.34%-33.80%-34.08%-117.64%
Pretax Margin
-20.90%-27.44%-33.08%-39.61%-47.83%-113.91%
Profit Margin
-20.90%-27.44%-33.08%-39.61%-47.83%-113.90%
FCF Margin
12.92%27.56%-63.52%-6.46%-108.13%-53.44%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-46.4846.48282.7641.73182.22
P/FCF Ratio
198.7399.24----
PS Ratio
25.6827.3538.4942.1931.6943.09